FDA is setting the tone for 2026: in silico evidence is becoming as indispensable as in vitro and in vivo in shaping regulatory decisions.
Every major public FDA session agenda announced for 2026 emphasizes modeling, simulation, and model-integrated evidence as key tools to accelerate complex generic and peptide drug development. This evolution reflects a broader transformation in how regulatory decisions are informed, with in silico now standing alongside in vitro and in vivo as a core pillar.
At InSilicoMinds, we offer end-to-end solutions that integrate PBPK modeling, bio-predictive simulations, virtual BE assessments, and regulatory-grade data pipelines, enabling the pharma and life sciences industry to design, evaluate, and deliver breakthrough therapies with greater speed, precision, and regulatory confidence.
2026 FDA focus highlights:
• May 5-6: Bioequivalence Innovations for Oral Generics
• September 23-24: Navigating the GLP-1 Generic Pathway
• October 14-15: Advancing BE Frameworks with In Silico Methods
• December 1-2: LAI Generics: Overcoming Technical Hurdles The message is clear: in silico is not the future, it is a current reality and a regulatory priority.
